SCM
EPRX

Squadron Capital Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Squadron Capital Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-680,000
Closed -$4.92M – 58
2026
Q1 		$4.92M Buy
680,000
+180,000
+36% +$1.45M 1.8% 17
2025
Q4 		$3.77M Buy
+500,000
New +$3.08M 1.6% 21

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Squadron Capital Management's EPRX Position: Q2 2026 in Review

Squadron Capital Management sold out of Eupraxia Pharmaceuticals (EPRX) in Q2 2026, closing a stake of 680,000 shares — an estimated $4.92M sold.

Squadron Capital Management first reported a position in EPRX in Q4 2025 and held it in 2 quarters. The position peaked at $4.92M in Q1 2026. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Squadron Capital Management reported no remaining Eupraxia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Squadron Capital Management sold 680,000 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $4.92M.
  • Squadron Capital Management first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Squadron Capital Management's Eupraxia Pharmaceuticals position peaked at $4.92M in Q1 2026.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.